New Biological Insights and Recent Therapeutic Advances in the Management of Lung Cancer


In these audio proceedings from a closed Think Tank meeting held in January 2015, the invited faculty discuss and debate some of the key clinical management issues in lung cancer as well as promising research strategies in this area. The roundtable discussion focused on key presentations and papers and actual cases managed in the practices of the faculty in which these data sets factored into their decision-making. This content is available in a number of formats for listening on the go with a mobile device or in the office or at home on a computer.
 

Listen to audio excerpts

Track 1: Case discussion: A 35-year-old woman and never smoker in respiratory failure from adenocarcinoma of the lung who requires rapid initiation of treatment
Track 2: Clinical experience with and activity of second-generation ALK inhibitors in patients with crizotinib-resistant disease
Track 3: Activity and tolerability of the ALK inhibitor ceritinib
Track 4: Case discussion: A woman with ALK-rearranged, advanced non-small cell lung cancer (NSCLC) receives full-dose ceritinib for 2 years
Track 5: Safety and activity of alectinib in patients with crizotinib-resistant ALK-rearranged NSCLC
Track 6: Potency and tolerability of investigational ALK inhibitors compared to crizotinib
Track 7: Efficacy of pemetrexed in ALK-rearranged NSCLC
Track 8: Targeted agents versus whole brain radiation therapy for patients with asymptomatic EGFR- or ALK-mutant CNS metastases
Track 9: Erlotinib and bevacizumab as first-line therapy for patients with advanced nonsquamous NSCLC harboring EGFR mutations
Track 10: Case discussion: A 68-year-old woman and never smoker with EGFR exon 19-deleted adenocarcinoma of the lung experiences a near complete response to erlotinib/bevacizumab followed by disease progression
Track 11: Response to rociletinib (CO-1686) after disease progression on erlotinib/bevacizumab
Track 12: IMPRESS: Results of a Phase III trial of gefitinib/chemotherapy versus chemotherapy in EGFR-mutant NSCLC after disease progression on first-line gefitinib
Track 13: Role of afatinib for patients with disease progression on erlotinib
Track 14: Activity and tolerability of rociletinib in EGFR-mutant, advanced NSCLC with the T790M resistance mutation
Track 15: Sequencing of EGFR tyrosine kinase inhibitors (TKIs)
Track 16: Clinical experience with rociletinib-associated hyperglycemia
Track 17: Case discussion: A 62-year-old man and never smoker with EGFR-mutant, advanced NSCLC receives AZD9291 on study after disease progression on erlotinib
Track 18: Activity and tolerability of AZD9291 in EGFR inhibitor-resistant, advanced NSCLC with the T790M mutation
Track 19: Comparison of AZD9291 and rociletinib
Track 20: Role of next-generation sequencing (NGS) in clinical practice
Track 21: A patient whose tumor was ALK wild type by FISH testing but subsequently identified by NGS as ALK rearranged
Track 22: Case discussion: An 80-year-old woman and never smoker with well-differentiated, HER2-mutant adenocarcinoma of the lung receives neratinib/temsirolimus on a clinical trial
Track 23: Spectrum of HER2 mutations in NSCLC
Track 24: Case discussion: A 77-year-old woman with BRAF-mutant, advanced NSCLC experiences a durable response to vemurafenib
Track 25: Case discussion: A 78-year-old woman with a RET-rearranged tumor identified through multiplex testing receives cabozantinib
Track 26: Case discussion: A 54-year-old man and smoker with pan-wild-type metastatic adenocarcinoma of the lung receives nivolumab for 2 years as second-line therapy
Track 27: Case discussion: A 76-year-old man and former remote smoker with heavily
treated metastatic squamous cell NSCLC experiences a greater than 15-month response to pembrolizumab
Track 28: Immune checkpoint inhibitor-associated toxicities
Track 29: Variability in assays for PD-L1 expression
Track 30: PD-L1 expression and response to anti-PD-1/anti-PD-L1 antibodies
Track 31: Pseudoprogression with anti-PD-1/anti-PD-L1 antibodies
Track 32: Case discussion: An 81-year-old woman with a remote smoking history with
pan-wild-type metastatic adenocarcinoma of the lung receives carboplatin/pemetrexed
Track 33: Organ function and performance status testing as means of identifying elderly patients who can tolerate chemotherapy
Track 34: Isolating the role of bevacizumab in elderly patients with previously untreated nonsquamous NSCLC: Secondary analyses of the ECOG-E4599 and PointBreak trials
Track 35: Factors affecting the decision to administer 4 versus 6 cycles of a platinum-based doublet for metastatic NSCLC
Track 36: Algorithm for maintenance treatment after a first-line platinum-based regimen
Track 37: Benefits of second-line ramucirumab/docetaxel observed in the Phase III REVEL study for patients with Stage IV NSCLC after disease progression on platinum-based therapy
Track 38: Perspective on the Phase III SQUIRE study of necitumumab combined with cisplatin/gemcitabine in advanced squamous cell NSCLC
Track 39: Case discussion: An 82-year-old man with advanced NSCLC has a VeriStrat® assay performed and experiences a durable benefit from erlotinib
Track 40: Predictive value of the VeriStrat assay for patients with NSCLC treated with second-line erlotinib or chemotherapy
Track 41: Case discussion: A 61-year-old man and 40 pack-year smoker undergoes lobectomy for a T2AN0M0, EGFR-mutant adenocarcinoma of the lung
Track 42: Clinical implications of the Phase III RADIANT study of adjuvant erlotinib with or without chemotherapy
Track 43: RADIANT subset analysis: Benefits of adjuvant erlotinib in patients with EGFR-mutant NSCLC
Track 44: SELECT: Results of a multicenter Phase II trial of adjuvant erlotinib for resected early-stage, EGFR-mutant NSCLC
Track 45: Potential role of EGFR TKIs as adjuvant therapy for patients with sensitizing EGFR mutations
 
FACULTY:
 
David P Carbone, MD, PhD
Barbara J Bonner Chair in
Lung Cancer Research
President-Elect, International Association
for the Study of Lung Cancer
Professor of Medicine
Director, James Thoracic
Oncology Center
James Cancer Center
The Ohio State University
Medical Center
Columbus, Ohio
 
Mark G Kris, MD
William and Joy Ruane Chair in
Thoracic Oncology
Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York
 
Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Vice Chair, Radiation Therapy
Oncology Group
Philadelphia, Pennsylvania
 
Geoffrey R Oxnard, MD
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
 
David R Spigel, MD
Program Director
Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee
 
Anne S Tsao, MD
Associate Professor
Director, Mesothelioma Program
Director, Thoracic
Chemo-Radiation Program
The University of Texas
MD Anderson Cancer Center
Department of Thoracic/Head and Neck
Medical Oncology
Houston, Texas
 
MODERATOR:
 
Neil Love, MD
Research To Practice
Miami, Florida